A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Clinical trial NCT03093922 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03093922
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-22
- Primary completion
- 2027-03-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.